Press Releases

Press Releases

July 17, 2018
CytomX Therapeutics Announces Closing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif. , July 17, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today

July 12, 2018
CytomX Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif. , July 12, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today

July 10, 2018
CytomX Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif. , July 10, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today

June 14, 2018
CytomX Announces Appointment of Lloyd A. Rowland Jr. as General Counsel

Brings 25 Years of Biotechnology and Pharmaceutical Legal Leadership Experience SOUTH SAN FRANCISCO, Calif. , June 14, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

May 31, 2018
CytomX to Present at the Jefferies 2018 Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , May 31, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, will present

May 16, 2018
CytomX Therapeutics Announces Presentations at 2018 ASCO Annual Meeting
- Preliminary first-in-human data to be presented from PROCLAIM-CX-072 trial of a PD-L1 Probody therapeutic as a monotherapy and in combination with ipilimumab - SOUTH SAN FRANCISCO, Calif. , May 16, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused
May 9, 2018
CytomX Therapeutics Announces First Quarter 2018 Financial Results

- Initial clinical data from the Phase 1/2 CX-072 program to be reported at American Society of Clinical Oncology Annual Meeting - SOUTH SAN FRANCISCO, Calif. , May 09, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company

Displaying 1 - 10 of 15